To The Moon

💬 Join the discussion: Vote in our poll below and share your take in the comments — every useful comment earns Tiger Coins! 🎁

Twenty U.S. stocks with market caps above $10 billion are trading at fresh all-time highs as of August 7, 2026. The top 10 span money-center and regional banking, AI-driven cybersecurity, aerospace & defense manufacturing, cystic fibrosis and oncology biopharma, wearable technology, industrial distribution, and molecular diagnostics—a cross-section pointing to bank earnings strength, cybersecurity demand re-rating on AI-era threats, and biotech pipeline catalysts as the market's current momentum drivers.

The top 10 tickers leading this cohort - $Bank of America(BAC)$, $Palo Alto Networks(PANW)$, $RTX Corp(RTX)$, $CrowdStrike Holdings, Inc.(CRWD)$, $Charles Schwab(SCHW)$, $Vertex Pharmaceuticals(VRTX)$, $Garmin(GRMN)$, $Fastenal(FAST)$, $Natera(NTRA)$, $Revolution Medicines, Inc.(RVMD)$

Financials leading the breakout: Big banks and brokers are setting the pace for the current wave of all-time highs, with $Bank of America(BAC)$ and $Charles Schwab(SCHW)$ both riding record quarterly results into fresh highs. Strong trading and investment-banking revenue, alongside a structural pickup in retail engagement, is reshaping how the Street values consumer-facing financial franchises.

Cybersecurity re-rates on AI-driven demand: $Palo Alto Networks(PANW)$ and $CrowdStrike Holdings, Inc.(CRWD)$ are being repriced as AI both threatens and defends enterprise networks. Palo Alto's CyberArk-fueled ARR acceleration and CrowdStrike's platform consolidation story are drawing some of the sharpest price-target increases in the market.

Defense and industrial backlogs hit records: $RTX Corp(RTX)$ posted a record $289 billion backlog on surging commercial aftermarket and defense demand, while $Fastenal(FAST)$ continues to show durable industrial distribution growth even with margin headwinds from tariffs and mix.

Biotech and diagnostics inflect on pipeline catalysts: $Vertex Pharmaceuticals(VRTX)$, $Natera(NTRA)$, and $Revolution Medicines, Inc.(RVMD)$ are each hitting highs on distinct but reinforcing stories — Vertex's non-CF product ramp, Natera's record testing volumes, and Revolution Medicines' regulatory momentum for daraxonrasib — underscoring how idiosyncratic clinical and commercial catalysts are driving healthcare outperformance even as the broader market grinds higher.

1. $Bank of America(BAC)$

• Core Business:
  Consumer and commercial banking, wealth management, and global markets/investment banking, serving roughly 67 million clients globally.

• Latest Developments:
  On July 30, 2026, JPMorgan raised its price target to $68 from $62.50, part of a broader wave of Street upgrades tied to a rotation from AI/semiconductor names into financials amid strong investment-banking and trading fee growth. BAC also raised its quarterly dividend by 14% to $0.32 per share.

• Q2 2026 Financial Highlights:
  Revenue of $31.6 billion, up 15% YoY and above the $30.78 billion consensus; net income rose 27% to $9.1 billion; diluted EPS of $1.21 beat estimates of $1.13, up 34% YoY. Sales and trading revenue jumped 33% to $7.2 billion and investment-banking fees rose 50% to over $2.1 billion; CET1 ratio was 11.2%.

• Price Target Outlook:
  Rating: Strong Buy. RBC Capital's Gerard Cassidy raised his target to $65 from $59 on July 15, 2026, while Goldman Sachs' Richard Ramsden raised his target to $71 from $63 the same day.

2. $Palo Alto Networks(PANW)$

• Core Business:
  AI-powered cybersecurity across network security, cloud security, and security operations, serving more than 80,000 enterprise customers globally.

• Latest Developments:
  On August 5, 2026, Barclays analyst Saket Kalia raised his price target to $370 from $315, citing continued momentum following the CyberArk and Chronosphere acquisitions. Palo Alto will report fiscal Q4 and full-year 2026 results on September 1, 2026.

• Latest Earnings Highlights (Q3 FY2026):
  Total revenue grew 31% YoY to $3.0 billion, including $388 million from CyberArk and Chronosphere; Next-Generation Security ARR rose 60% YoY to $8.1 billion; adjusted EPS of $0.85 beat estimates of $0.80. GAAP operating loss was $183 million due to acquisition-related costs.

• Price Target Outlook:
  Rating: Strong Buy. BofA raised its target to $420 from $330, and Morgan Stanley raised its target to $387 from $320, naming PANW its top cybersecurity pick.

3. $RTX Corp(RTX)$

• Core Business:
  Aerospace and defense across three segments — Collins Aerospace, Pratt & Whitney, and Raytheon — spanning commercial aftermarket, OE, and missile defense systems.

• Latest Developments:
  On July 23, 2026, RTX reached an agreement to sell Raytheon's Blue Canyon Technologies business for $620 million and raised full-year 2026 adjusted sales guidance to $95.0–$96.0 billion from $92.5–$93.5 billion.

• Q2 2026 Financial Highlights:
  Sales of $24.7 billion, up 14% YoY (16% organically), beat the $22.83 billion consensus; adjusted EPS of $1.89 beat estimates of $1.66, up 21% YoY. Backlog reached a record $289 billion, up 22% YoY; free cash flow was $2.9 billion.

• Price Target Outlook:
  Rating: Strong Buy. Morgan Stanley's Kristine Liwag raised her target to $240 from $220 on July 23, 2026, and Wells Fargo raised its target to $230.

4. $CrowdStrike Holdings, Inc.(CRWD)$

• Core Business:
  Cloud-native cybersecurity platform protecting endpoints, cloud workloads, identity, and data for enterprise customers.

• Latest Developments:
  CrowdStrike will report fiscal Q2 2027 results (quarter ended July 31, 2026) on August 26, 2026. The company said its Fal.Con 2026 conference sold out at a record pace, and its 2026 Threat Hunting Report highlighted AI-driven adversary tactics.

• Latest Earnings Highlights (Q1 FY2027):
  Total revenue grew 26% YoY to $1.39 billion; record net new ARR of $256 million; record free cash flow of $468 million. Management raised full-year net new ARR growth guidance to 27.7% at the midpoint.

• Price Target Outlook:
  Rating: Strong Buy. BofA raised its target to $230 from $187.50 on July 27, 2026, citing AI-driven security demand.

5. $Charles Schwab(SCHW)$

• Core Business:
  Brokerage, wealth management, banking, and advisory services for individual investors and independent investment advisors.

• Latest Developments:
  Schwab completed its acquisition of Forge Global to add private-markets capabilities and launched Schwab Crypto spot trading for Bitcoin and Ethereum during the quarter.

• Q2 2026 Financial Highlights:
  Record net revenue of $7.07 billion, up 21% YoY, beating the $6.90 billion consensus; adjusted EPS of $1.62 beat estimates of $1.55, up 42% YoY. Core net new assets rose nearly 50% to $120 billion; daily average trades were up 28% to 11.9 million.

• Price Target Outlook:
  Rating: Strong Buy. Raymond James raised its target to $145 from $137 on July 22, 2026, and Barclays raised its target to $125 from $122.

6. $Vertex Pharmaceuticals(VRTX)$

• Core Business:
  Biotech developing therapies for cystic fibrosis (TRIKAFTA/KAFTRIO, ALYFTREK), sickle cell disease/beta thalassemia (CASGEVY), and non-opioid acute pain (JOURNAVX).

• Latest Developments:
  On July 13, 2026, Vertex announced a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, adding rare endocrine diseases as a fifth commercial pillar; the deal is expected to close in Q3 2026.

• Q2 2026 Financial Highlights:
  Total revenue rose 12% YoY to $3.33 billion, beating the $3.22 billion consensus; CASGEVY revenue grew 151% YoY to $76 million and JOURNAVX revenue more than quadrupled to $50 million. Non-GAAP EPS of $4.73 narrowly missed the $4.74–4.75 estimate. Full-year revenue guidance raised to $13.1–$13.2 billion.

• Price Target Outlook:
  Rating: Strong Buy. TD Cowen's Phil Nadeau raised his target to $550 from $525, and BofA raised its target to $600 from $598.

7. $Garmin(GRMN)$

• Core Business:
  Consumer and professional GPS and wearable technology across Fitness, Outdoor, Aviation, Marine, and Auto OEM segments.

• Latest Developments:
  On July 29, 2026, Garmin raised full-year 2026 guidance to approximately $8.05 billion in revenue and $10.00 pro forma EPS, up from $7.9 billion and $9.35, citing strong first-half performance; shares jumped as much as 17% on the news.

• Q2 2026 Financial Highlights:
  Record revenue of $2.02 billion, up 11% YoY, beat the $1.94 billion consensus; pro forma EPS of $2.81 beat estimates of $2.29 (or $2.27 per Zacks), up 29% YoY. Fitness segment revenue surged 25% to $757 million; operating margin expanded to 30.4%.

• Price Target Outlook:
  Rating: Buy. Barclays' Tim Long raised his target to $297 from $238 on July 30, 2026, and Morgan Stanley raised its target to $289 from $249.

8. $Fastenal(FAST)$

• Core Business:
  Industrial and construction supply distribution through onsite locations, vending, and digital ordering platforms (FMI technology).

• Latest Developments:
  Fastenal reported that 2026 capital spending remains guided at $310–$330 million, with Digital Footprint sales expected to represent 63%–64% of annual sales; management cited continued tariff-cost management.

• Q2 2026 Financial Highlights:
  Net sales of $2.39 billion, up 14.7% YoY, beat the $2.34 billion consensus; diluted EPS of $0.33 was in line with estimates, up from $0.29 a year earlier. Net income rose 15.9% to $382.8 million, with net margin expanding to 16.0%.

• Price Target Outlook:
  Rating: Buy. Morgan Stanley's Christopher Snyder raised his target to $52 from $48 on July 16, 2026, while Barclays lowered its target to $46 from $47.

9. $Natera(NTRA)$

• Core Business:
  Cell-free DNA and molecular diagnostics testing across oncology (Signatera), women's health, and organ health (Prospera).

• Latest Developments:
  On August 6, 2026, Natera reported that Signatera received FDA companion-diagnostic approval in bladder cancer, Japanese regulatory approval for colorectal cancer, and European IVDR certification; the stock surged over 20% following the report.

• Q2 2026 Financial Highlights:
  Total revenue of $752.8 million, up 37.7% YoY, beat consensus by nearly 14%; gross margin was approximately 65%. The company processed a record ~1.04 million tests; full-year revenue guidance raised to $2.85–$2.91 billion from $2.74–$2.82 billion.

• Price Target Outlook:
  Rating: Strong Buy. JPMorgan raised its target to $360 from $315 on August 7, 2026, and Morgan Stanley raised its target to $355 from $310.

10. $Revolution Medicines, Inc.(RVMD)$

• Core Business:
  Late-stage clinical oncology company developing RAS(ON) inhibitor therapies (daraxonrasib, elironrasib, zoldonrasib) for RAS-addicted cancers, including pancreatic and lung cancer.

• Latest Developments:
  On July 22, 2026, the FDA accepted for review Revolution Medicines' New Drug Application for daraxonrasib in previously treated metastatic pancreatic cancer; the drug also received FDA Breakthrough Therapy Designation for RAS-mutant non-small cell lung cancer.

• Q2 2026 Financial Highlights:
  The company remains pre-revenue; net loss widened to $644 million from $248 million a year earlier, including a $151 million non-cash warrant charge. Cash and investments stood at $3.9 billion after $2.2 billion raised via April stock and convertible-note offerings.

• Price Target Outlook:
  Rating: Strong Buy. Guggenheim's Michael Schmidt raised his target to $240 from $235, and JPMorgan raised its target to $227 from $205.

🐯 Your Turn: Join the Discussion

📊 Quick Poll: Of these 10 all-time-high stocks, which sector do you think has the most room left to run?

A) Banking (BAC, SCHW)

B) Cybersecurity (PANW, CRWD)

C) Aerospace & Defense (RTX)

D) Biopharma & Diagnostics (VRTX, NTRA, RVMD)

Vote below, then tell us:

• Why you picked that sector

• Which single name on this list you'd buy today

• Whether you think this cybersecurity re-rating still has legs, or is due for a pullback

🎁 Every useful and thoughtful comment will receive Tiger Coins.